In previous studies, we have shown that losartan possesses nitric oxide-dependent antithrombotic properties in various models of hypertension in rats. It was demonstrated that stimulation of AT 2 -receptors plays an important role in the pharmacological effects of AT 1 -receptor antagonists. Thus, in this study, we examine the participation of AT 2 -receptors in the antithrombotic action of losartan in renal hypertensive rats on venous thrombosis induced by a two-hour ligation of the vena cava. Losartan administration (30 mg/kg, p.o.) resulted in a marked decrease in thrombus weight (by 85%, p<0.001). PD123319, an AT 2 -receptor antagonist (10 mg/kg, i.v.), administered concomitantly with losartan, abolished its antithrombotic effect, whilst it had no influence on thrombus weight when given alone. A significant decrease in systolic blood pressure was observed in animals given losartan. PD123319 administration did not abolish this action of losartan and did not alter blood pressure when given alone. No changes in prothrombin time, activated partial thromboplastin time, or euglobulin clot lysis time were observed in animals administered losartan and/or PD123319. Similarly, primary haemostatics evaluated by bleeding time and platelet count did not change in any group of rats. In conclusion, we have shown that AT 2receptor stimulation is involved in the antithrombotic action of losartan in renal hypertensive rats.
Introduction
During the last few years much experimental and clinical data have suggested a role for the reninangiotensin-aldosterone system (RAAS) in haemostasis. It has been shown, among other things, that angiotensin II (Ang II) influences coagulation and fibrinolysis by induction of plasminogen activator inhibitor (PAI-1) production in vitro and in vivo, [1] [2] [3] stimulation of tissue factor expression, 4 potentiation of platelet aggregation 5 and stimulation of expression and release of the adhesion molecule ICAM-1, 6 thus promoting thrombosis.
Nonpeptide, selective AT 1 -receptor antagonists are a new class of antihypertensive drugs, among which losartan (LOS) was the first to be introduced into clinical use. 7, 8 Recent data suggest that, not only AT 1 -receptor blockade, but also excessive stimulation of AT 2 -receptors, in conditions of increased levels of circulating Ang II, play an important role in the pharmacological effects observed during treatment with these drugs. 8, 9 The function of the AT 2 -receptor is far from being clear and is still a matter of debate. Generally, in the cardiovascular system, stimulation of AT 2 -receptors inhibits cell growth and proliferation, 10 although some authors have observed the opposite effect. 11 It has been reported that, in rat endothelial cells, isolated coronary microvessels and aorta in AT 2transgenic mice, Ang II is able to stimulate nitric oxide (NO) synthesis, [12] [13] [14] as well as cGMP 14 which has been proven to play a biological role in vascular haemostasis. 15 This effect is mediated via AT 2receptors.
Previously, we have shown that acute losartan administration to two-kidney, one-clip renal hypertensive and spontaneously hypertensive rats results in an NO-dependent antithrombotic effect. 16, 17 The present study was undertaken to investigate the participation of AT 2 -receptors in this action.
Materials and methods

Animals and induction of renovascular hypertension
Male Wistar rats weighing 180-240 g were used throughout the study. The animals were housed in a room with a 12-hour light/dark cycle, in group cages as appropriate, were given tap water and fed a standard rat chow.
A two-kidney, one-clip (2K-1C) model of renovascular hypertension was induced by a partial, standardised clipping of the left renal artery as described elsewhere. 17 The experiments were conducted six weeks after this procedure.
Procedures involving animals and their care were conducted in conformity with national and international laws and Guidelines for the Use of Animals in Biochemical Research (Thromb Haemost 1987; 58: 1078-84.)
Drugs
Losartan (Du Pont Merck Pharmaceutical Co., USA), PD 123319 (RBI, USA), pentobarbital (Vetbutal, Polfa, Poland) and 3.13% sodium citrate (Polish Chemical Reagents, Gliwice, Poland) were used in the experiments.
Experimental protocol and venous thrombosis model
The animals were randomly divided into groups and received losartan (LOS, 30 mg/kg, p.o.), PD123319 (PD, 10 mg/kg, i.v.) or LOS + PD123319 concomitantly. The control animals (VEH) were given distilled water or 0.9% NaCl (the same vol-ume and route).After two hours, venous thrombosis was induced as previously described by others. 18 Briefly, the animals were anaesthetised with pentobarbital (40 mg/kg, i.p.), the abdomen was opened, the vena cava was carefully separated from surrounding tissues and ligated tightly with a cotton thread just below the left renal vein. The abdomen was then closed with a double layer of sutures. After two hours, the abdomen was reopened, the vena cava was dissected longitudinally and the formed thrombus was removed. Obtained thrombi were kept at 37°C for 24 hours and after this time their dry weight was measured.
Blood pressure measurement
The systolic blood pressure (SBP) was estimated five minutes before the induction of venous thrombosis using the 'tail cuff' method (Student Oscillograph, Harvard Rat Tail Blood Pressure Monitor), according to Ikeda. 19 Each value was the average of three consecutive readings.
Bleeding time, haemostatic analyses and platelet count 'Template' bleeding time (BT) was measured just before venous thrombosis induction by longitudinal incision of the rat tail as previously described by Dejana et al. 20 Blood samples (2 ml) were taken from the heart after the thrombus was removed from the vena cava.The blood was mixed with 3.13% sodium citrate in a volume ratio 9:1 and centrifuged for 20 minutes at 490 g, 4°C. Prothrombin time (PT), activated partial thromboplastin time (APTT) and euglobulin clot lysis time (ECLT) were determined by routine laboratory assays.
Platelets were counted by a phase contrast microscope after dilution of the blood by the Unopette system (Becton -Dickinson, New Jersey, USA).
Statistical analysis
Multiple group comparisons were performed by one-way analysis of variance (ANOVA) with a Student-Neuman-Keuls post test. The data are pre-sented as mean±SEM.A value of p<0.05 was considered statistically significant.
Results
In VEH rats the dry thrombus weight was 4.05±0.58 mg. Losartan administration resulted in a pronounced decrease in this parameter (0.7±0.09 mg, p<0.001 vs.VEH). PD123319 administered concomitantly with losartan abolished its antithrombotic effect (2.73±0.28, p<0.05 vs. LOS), while it had no influence on the thrombus weight when given alone (3.23±0.37, ns vs.VEH) (Figure 1) .
Losartan administration caused a significant decrease in systolic blood pressure from 163±4 mmHg to 131±4 mmHg (p<0.01) and this effect was not abolished by concomitant PD123319 administration (123±6 mmHg, ns vs. LOS). PD123319 administered alone did not alter blood pressure (166±4 mmHg, ns vs.VEH) ( Figure 2 ).
No changes in haemostatic analyses (prothrombin time, activated partial thromboplastin time and euglobulin clot lysis time) were observed in animals administered with LOS and/or PD123319 (Table 1) . Similarly, primary haemostasis, evaluated by bleeding time and platelet count, was not changed in any group of rats (Table 1) .
Discussion
It has been shown that, in the presence of a specific AT 1 -receptor antagonist, Ang II can bind to unblocked AT 2 -receptors and, at least partially, mediate the effect of the AT 1 antagonist. 8,21 AT 1receptors are involved in both the pressor as well as vascular and cardiac hypertrophic effects of Ang II. 7 Several studies suggest that AT 1 -and AT 2receptors are functionally antagonistic. 7, 8, 21 In this study we have shown that acute losartan administration to 2K-1C hypertensive rats results in about 85% inhibition of venous thrombus formation, which is in line with our previous observations. 17 Administration of PD123319, the selective AT 2 -receptor antagonist, at a dose in which it reaches plasma concentrations known to provide complete blockade of AT 2 -receptors, almost completely abolished the antithrombotic PAPER effect of losartan. These results suggest that the decrease of venous thrombus formation observed after losartan administration depends mainly on AT 2 -receptor activation. AT 2 -receptors are re-expressed or up-regulated after vascular injury, myocardial infarction or cardiac failure. 22, 23 It has been reported recently that AT 2 -receptor stimulation modulates the antigrowth effect of Ang II on vascular smooth muscle and endothelial cells, 12 inhibits the proliferation of rat coronary artery 13 and fibrillar collagen synthesis in a hamster heart. 24 The beneficial effect of an AT 1 -antagonist on left ventricular diastolic and systolic volume, as well as cardiomyocyte size, in the course of heart failure induced by coronary ligature in rats, was shown to be related to AT 2 -receptor stimulation. 25 Similarly, a reduction of infarct size by AT 1 -antagonism in pigs involves AT 2 -receptor activation. 26 The molecular mechanism responsible for these effects seems to be related to the release of nitric oxide and/or prostacyclin due to AT 2 -receptor stimulation.
A number of recent studies have suggested the existence of a link between Ang II and the kinin/ nitric oxide system in the vessel wall. Ang II stimulates NO synthesis via AT 2 -receptors in endothelial cells, 12 isolated coronary microvessels 13 and aorta in AT 2 -transgenic mice. 14 It cannot be excluded that the bradykinin-NO-cGMP vasodilator cascade mediated by the AT 2 -receptor plays a protective role, not only in blood pressure regulation, 27 but also against development of the thrombotic process. NO is a well known stimulator of fibrinolysis, 28, 29 and inhibitor of platelet aggregation and adhesion as well as neutrophil adhesion to endothelial cells. [30] [31] [32] Since, in the present study,AT 2 -receptor blockade did not completely reverse the antithrombotic effect of losartan, participation of other mechanisms in its action cannot be excluded. During losartan treatment, the concentration of the Ang II degradation product, angiotensin-(1-7) is enhanced. 33 This biologically active heptapeptide is able to stimulate the kinin-NO system. 34 Preliminary studies from our laboratory show that the participation of angiotensin-(1-7) in the antithrombotic action of losartan should also be taken into account. 35 Losartan is a potent stimulus for prostaglandin E 2 and prostacyclin synthesis in cultured endothelial cells. 36 Moreover, recent observation demonstrates that this drug is a weak, competitive antagonist of human 37 and rat 38 platelet TXA 2 /PGH 2 receptors. On the basis of the above data, the participation of prostaglandins could be expected in the antithrombotic effect of losartan. In our previous study 16 we have investigated the role of prostaglandins in the antithrombotic effect of losartan. In our experimental model, inhibition of prostaglandin synthesis by indomethacin reduced We could thus conclude that AT 2 -receptors, rather than TXA 2 /PGH 2 receptors and prostaglandins, are predominantly involved in the antithrombotic effect of losartan. Moreover, we have shown previously that the treatment of animals with L-NAME completely abolished the antithrombotic effect of losartan. On the basis of these findings,an NO-dependent mechanism of the antithrombotic action of losartan must first be taken into consideration. Nevertheless, the role of prostaglandins and TXA 2 /PGH 2 receptors in the antithrombotic effect of losartan needs further evaluation.
The primary haemostatic and basal parameters of fibrinolysis and coagulation measured in the systemic circulation after losartan treatment were not significantly changed. This is in agreement with our previous 16, 17 as well as other studies. 39 It is possible therefore, that the antithrombotic effect of losartan is a localised phenomenon which may result either in locally increased fibrinolytic activity or inhibition of platelet/leukocyte function. To our knowledge, there are no data concerning the influence of AT 2 -receptors on the haemostatic system.
The finding that stimulation of AT 2 -receptors results in enhanced NO synthesis in the vasculature suggests the possible involvement of AT 2receptors in basal blood pressure maintenance, as well as a contribution to the antihypertensive action of AT 1 -receptor blockade. In our conditions, the blockade of AT 2 -receptors with PD123319 did not alter basal blood pressure and did not reverse the antihypertensive action of losartan. A similar observation was reported by Barber et al. in spontaneously hypertensive rats 40 and Levy et al. in normotensive rats. 11 On the other hand, in 2-kidney, 1 figure-8 wrap hypertensive rats (Grollman hypertension) and in salt-restricted rats, combined administration of losartan and PD123319 prevented the decrease in systolic blood pressure observed with losartan alone. 41, 42 Moreover, the study of Scheuer and Perrone 27 has shown that, in conditions of AT 1 -receptor blockade,AT 2 -receptors mediate a hypotensive effect in the response to administration of exogenous Ang II. We can not exclude that, in our study, the increase of endogenous plasma angiotensin II after AT 1 -receptor blockade was too low to trigger this mechanism. Nevertheless, as we have demonstrated previously, the changes in blood pressure were not correlated with the antithrombotic effects of drugs inhibiting the RAAS. 16, 17, 43 In conclusion, we have demonstrated that AT 2receptor stimulation, at least partially, can be involved in the antithrombotic effect of losartan in renal hypertensive rats. It is complementary to our previous study which showed an NO-dependent antithrombotic effect of losartan in a venous thrombosis model in rats. However, the discrepancy between the influence of AT 2 -receptor blockade on venous thrombus formation and blood pressure needs to be elucidated. Moreover, our data present further support for the beneficial influence of increased Ang II levels during losartan treatment.
